Soligenix Reports Positive Interim and Comparative Data for CTCL Treatment HyBryte
Soligenix announced consistent interim response rates from its phase 3 FLASH2 study and positive comparative results for HyBryte against Valchlor in cutaneous T-cell lymphoma, highlighting progress for a disease with limited treatment options.
Soligenix Inc. (NASDAQ: SNGX) released a clinical update on its cutaneous T-cell lymphoma (CTCL) research, providing interim data from the phase 3 FLASH2 study and positive comparative results for its investigational therapy HyBryte. The company reported that the overall blinded aggregate response rate in patients who have completed treatment remains consistent with prior reporting, indicating sustained efficacy. Additionally, a study comparing HyBryte to Valchlor, an existing treatment for CTCL, yielded positive results, reinforcing the potential of HyBryte as a new therapeutic option.
CTCL, a rare form of non-Hodgkin lymphoma primarily affecting the skin, can cause persistent skin lesions, plaques, and tumors, often leading to significant morbidity. According to the National Cancer Institute, treatment options are limited, making the advancement of new therapies critical. Soligenix's progress in both the FLASH2 study and the comparative analysis underscores the company's commitment to addressing unmet medical needs in serious conditions.
The interim analysis from the FLASH2 study, which remains blinded, showed that the response rates are consistent with earlier data, suggesting that HyBryte continues to demonstrate activity in CTCL patients. While the company did not disclose specific numerical results, the consistency of the response rate is a positive signal for the ongoing trial. The comparative study results against Valchor further strengthen the case for HyBryte, though details of the comparison were not fully disclosed in the announcement.
Soligenix's focus on CTCL is particularly noteworthy given the disease's rarity and the limited treatment landscape. The company's ability to generate both clinical trial momentum and positive data is a critical combination in biotechnology, especially for diseases with few approved therapies. Investors and clinicians alike will be watching for further updates from the FLASH2 study and potential regulatory discussions.
For more information on Soligenix and its pipeline, visit the company's newsroom at https://ibn.fm/SNGX. Additional details about the company's work can be found through BioMedWire, a communications platform focused on biotechnology and life sciences developments.